2021
DOI: 10.1016/j.diabres.2021.108820
|View full text |Cite
|
Sign up to set email alerts
|

The future of insulin therapy

Abstract: Dedicated to Dr. Peter Kurtzhals, a brilliant scientist and a great person, who has pioneered so many insulin innovations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
28
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 40 publications
(28 citation statements)
references
References 51 publications
0
28
0
Order By: Relevance
“…Like Icodec, the insulin moiety contains paired B-chain substitutions (Tyr B16 →Glu and Phe B25 →His). Clinical testing in patients with T2D demonstrated a half-life of 17 days with near-peakless PK/PD profile for once-a-week dosing [ 120 , 121 ]. Alternative embodiments of this strategy have been described [ 122 ], including a heterodimeric two-chain SCI-F c fusion [ 123 ].…”
Section: Basal Insulin Analogsmentioning
confidence: 99%
“…Like Icodec, the insulin moiety contains paired B-chain substitutions (Tyr B16 →Glu and Phe B25 →His). Clinical testing in patients with T2D demonstrated a half-life of 17 days with near-peakless PK/PD profile for once-a-week dosing [ 120 , 121 ]. Alternative embodiments of this strategy have been described [ 122 ], including a heterodimeric two-chain SCI-F c fusion [ 123 ].…”
Section: Basal Insulin Analogsmentioning
confidence: 99%
“…A second ultra-long-acting formulation in development is basal insulin Fc, in which a novel single-chain variant of insulin has been combined with a human IgG 2 Fc domain to yield a fusion protein that has a peak-to-trough ratio suggestive of a prolonged half-life. 63 It thus appears that we may have the potential to administer insulin once a week, with the anticipation that this approach should improve patient willingness to initiate and adhere to insulin therapy in practice. 68 However, the potential for prolonged hypoglycaemia in response to unexpected lifestyle circumstances requires further study and long-term safety will need careful evaluation.…”
Section: Once Weekly Basal Insulinmentioning
confidence: 99%
“…70 Indeed, compared to glargine U-100, basal insulin peglispro has been shown to offer greater A1c reduction, coupled with reduced nocturnal hypoglycaemia and less weight gain, in patients with T2DM and T1DM. 63 However, the development of basal insulin peglispro was halted due to adverse effects, including greater hepatic fat, an increased propensity for elevated transaminases, higher serum triglycerides, and injection site reactions. 69 These findings may represent inadequate peripheral insulin action in inhibiting lipolysis.…”
Section: Hepato-preferential Insulinmentioning
confidence: 99%
See 1 more Smart Citation
“…I believe that no one else could have treated this topic better than Matthew, the creator of the 'treat to target' scheme. Prof. Tim Heise has been involved in most any development of new insulin and in his article gives on overview of the future of insulin therapy [6]. Finally, we have the unique contribution of Dr. Paolo Di Bartolo, President of the Associazione Medici Diabetologi (AMD, the Italian Scientific Society of Specialists in Diabetes) and Prof. Robert Ecker, Past President of the American Diabetes Association (ADA).…”
Section: Introductionmentioning
confidence: 99%